Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lebrikizumab in Moderate Atopic Dermatitis and High Itch Burden
NCT07006792Phase 4Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2025
- Primary completion
- May 2026
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 4 trial of lebrikizumab in atopic dermatitis (AD), sponsored by Eli Lilly and Company. Started Jun 2025; status: completed.
02
Drugs
lebrikizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07006792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07006792.